Business
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are being optimized. Four core innovative products are poised for commercialization, and significant advancements have been made in overseas market expansion. Two mRNA technology vaccines have simultaneously received clinical trial approvals in bot
About this update from Aim Vaccine Co., Ltd. Class H
[{"type":"text","content":"HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are being optimized. Four core innovative products are poised for commercialization, and significant advancements have been made in overseas market expansion. Two mRNA technology vaccines have simultaneously received clinical trial approvals in both the PRC and the U.S., leading to optimistic forecasts from institutions. A recent report[1] by DBS Bank predicts nearly 60% upside potential for the company's stock price compared to current levels.","length":754,"tagName":"p"},{"type":"text","content":"Confirmed Major Products Expected to Achieve Profitability by 2026","length":66,"tagName":"p"},{"type":"text","content":"According to the interim report, AIM's 13-valent pneumococcal conjugate vaccine has applied for market registration and completed on-site verification. The application for its serum-free rabies vaccine has been accepted, while the 23-valent pneumococcal polysaccharide vaccine has finished Phase III clinical serological tests and is set to enter the statistical unblinding phase. The iterative process for the high-efficiency diploid rabies vaccine is currently in Phase III clinical trials, expected to conclude by the end of 2025, with a market registration application planned for 2026.","length":594,"tagName":"p"},{"type":"text","content":"DBS Bank's research report forecasts that AIM Vaccine is likely to achieve profitability by 2026. By then, AIM is projected to become the leading manufacturer of rabies and pneumococcal vaccines in the PRC, capturing approximately 20% and 10% market shares, respectively. Sales from 2025 to 2027 are anticipated to grow at a compound annual growth rate of 45%.","length":364,"tagName":"p"},{"type":"text","content":"mRNA Technology Platform Gains International Recognition, Leading R&D Innovation in the Industry ","length":100,"tagName":"p"},{"type":"text","content":"As highlighted in the interim report, AIM Vaccine continues to excel in R&D, currently possessing 20 vaccine products in development targeting 12 diseases, with 23 clinical approvals and 24 clinical trials un...